NEW YORK, January 5, 2017 /PRNewswire/ --
Stock-Callers.com shifts focus on these Medical Laboratories and Research equities: Thermo Fisher Scientific Inc. (NYSE: TMO), Laboratory Corp. of America Holdings (NYSE: LH), VWR Corp. (NASDAQ: VWR), and PerkinElmer Inc. (NYSE: PKI). Medical Laboratories are a vital part of the global healthcare system, as they provide information to healthcare professionals about the severity, onset, and reason of patients' ailments. Medical Laboratories include biological, bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
Thermo Fisher Scientific
On Wednesday, shares in Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc. recorded a trading volume of 2.16 million shares, which was above their three months average volume of 1.93 million shares. The stock ended at $145.16, rising 1.04% from the last trading session. The Company's shares have gained 2.40% in the last one month and 2.88% on an YTD basis. The stock is trading above its 50-day moving averages by 0.01%. Furthermore, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide, have a Relative Strength Index (RSI) of 57.17. Visit us today and access our complete research report on TMO at:
Laboratory Corp. of America
Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' stock finished yesterday's session 0.80% higher at $130.10. A total volume of 1.18 million shares was traded, which was higher than their three months average volume of 737,400 shares. The Company's shares have gained 4.51% in the last one month and 1.34% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.38% and 0.11%, respectively. Furthermore, shares of Laboratory Corp. of America Holdings, which operates as an independent clinical laboratory company worldwide, have an RSI of 62.12.
On January 03rd, 2017, the Company announced that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted. In order to exercise the option to convert all or a portion of the Zero Coupon Notes, holders must validly surrender their Zero Coupon Notes at any time during the calendar quarter through the close of business at 5:00 p.m. ET on March 31st, 2017. Should Zero Coupon Notes be converted, Laboratory Corp. would be required to pay holders in cash for the accreted principal amount of the securities to be converted, with the remaining amount, if any, to be satisfied with shares of Common Stock. The shares required for settlement of the Zero Coupon Notes are included in Laboratory Corp.'s computation of fully diluted EPS. The complimentary report on LH can be downloaded at:
At the closing bell on Wednesday, shares in Radnor, Pennsylvania-based VWR Corp. climbed 1.54%, ending the day at $25.66. The stock recorded a trading volume of 861,182 shares, which was above its three months average volume of 844,480 shares. The Company's shares have advanced 1.14% in the last one month and 2.52% since the start of this year. The stock is trading 1.94% below its 50-day moving average. Moreover, shares of VWR Corp., which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have an RSI of 52.53.
On December 19th, 2016, VWR announced that it has been recognized as a 2016 Healthiest 100 Workplace in America, an awards program presented by Springbuk®. Award applicants were evaluated across six key categories: Vision, Culture/Engagement, Learning, Expertise, Metrics and Technology. Over 5,000 employers applied for the Award nationally. Register for free on Stock-Callers.com and access the latest research report on VWR at:
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock ended the day 0.59% higher at $53.30, with a total trading volume of 497,274 shares. The Company's shares have gained 4.53% in the last month and 2.21% on an YTD basis. The stock is trading 2.93% above its 50-day moving average and 0.78% above its 200-day moving average. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide, have an RSI of 58.83.
On December 22nd, 2016, Varian Medical Systems announced an agreement to acquire the Medical Imaging business of PerkinElmer, as an addition to the Varian Imaging Components business, which is slated to become an independent public company, Varex Imaging Corporation, through a previously announced separation expected to be completed in January 2017. The acquisition is expected to close after the planned separation of Varex from Varian and following receipt of required regulatory approvals. Varex will pay $276 million to acquire PerkinElmer's Medical Imaging business. Get free access to your research report on PKI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA